Normann, L. S., Haugen, M. H., Hongisto, V., Aure, M. R., Leivonen, S., Kristensen, V. N., . . . Mælandsmo, G. M. (2023). High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. Public Library of Science (PLoS).
芝加哥风格引文Normann, Lisa Svartdal, et al. High-throughput Screen in Vitro Identifies Dasatinib as a Candidate for Combinatorial Treatment with HER2-targeting Drugs in Breast Cancer. Public Library of Science (PLoS), 2023.
MLA引文Normann, Lisa Svartdal, et al. High-throughput Screen in Vitro Identifies Dasatinib as a Candidate for Combinatorial Treatment with HER2-targeting Drugs in Breast Cancer. Public Library of Science (PLoS), 2023.
警告：这些引文格式不一定是100％准确.